Patient Gateway

RSS Feed

First-line immune checkpoint inhibitors versus chemotherapy in delaying quality of life deterioration in advanced NSCLC: a systematic review and meta-analysis

68Ga-granzyme B (68Ga-NOTA-GSI) PET/CT for predicting immunotherapy response and progression free survival in NSCLC

Impact of antibiotic exposure on survival outcomes in NSCLC patients treated with third-generation EGFR-TKIs

EGFR/TP53 共突变 NSCLC：联合治疗策略开启个体化治疗新路径_腾讯新闻

Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20 NSCLC

In silico design of a novel therapeutic multi-epitope vaccine against NSCLC: a reverse vaccinology approach

Akeso Biopharma (09926): The National Medical Products Administration has approved the marketing application for the third indication of Ivonescimab (Ivofang, PD-1/VEGF), for use in first-line treatment of squamous non-small cell lung cancer (sq-NSCLC).

涂水平教授：HER2 过表达 NSCLC 的精准检测辨析与 ADC 驱动下的治疗变革_腾讯新闻

Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI–treated NSCLC: a cross-database real-world study

Cutaneous immune-related adverse events independently predict overall survival with a grade-dependent association in ICI-treated advanced NSCLC: a time-dependent analysis